Currently, accurate molecular pathological information is vital for the precise diagnosis and clinical management of gliomas in the brain; their key molecular features, including isocitrate dehydrogenase (IDH) mutations, 1p/19q co-deletion, and the H3 K27M mutation, are included in the World Health Organization (WHO) 2016 classification of tumors of the central nervous system [19, 24, 25]. Here, IDH1 is linked to glioma.